Advertisement
The Leading Source for Pharmaceutical & Biopharmaceutical Manufacturing News
Subscribe to Pharmaceutical Processing

The Lead

FTC Clears Sun Pharma's $4B Purchase of Ranbaxy

January 30, 2015 | News | Comments

Sun Pharmaceuticals will sell the rights to one generic drug as part of its purchase of competitor Ranbaxy Laboratories, U.S. antitrust regulators said Friday. The Federal Trade Commission said the companies will sell Ranbaxy's interests in generic minocycline, an antibiotic used to treat several types of infections.

TOPICS:
View Sample

FREE Daily Email Newsletter

Contract Manufacturers Unlikely to Benefit from Biosimilars

January 30, 2015 9:45 am | by Andrew Szal, Editor, Pharmaceutical Processing | News | Comments

Contract pharmaceutical manufacturers are unlikely to benefit from the rise of generic biological drugs in the U.S., according to an analysis by PharmSource. The company said large drug companies and those with significant commercialization and manufacturing partnerships are likely to dominate the initial market for those drugs, called biosimilars -- leaving out companies relying on contract manufacturing.

TOPICS:

FDA Approves BMS’s Evotaz™ for the Treatment of HIV-1 Infection in Adults

January 30, 2015 8:42 am | News | Comments

Evotaz is coformulated to be one pill, once-daily, combining the protease inhibitor atazanavir, which is marketed as Reyataz (atazanavir 200 mg/300 mg) capsules, and cobicistat, a pharmacokinetic enhancer marketed by Gilead Sciences.   

TOPICS:

Dendreon Reaches Agreement for Valeant to Serve as “Stalking Horse Bidder” in Court-Supervised Sales Process

January 30, 2015 8:37 am | News | Comments

Under the terms of the agreement, Valeant would acquire the world-wide rights of PROVENGE® (sipuleucel-T) and certain other Dendreon assets for $296 million, subject to higher and better bids.          

TOPICS:
Advertisement

Lilly Beats Wall Street Fourth Quarter Forecasts

January 30, 2015 8:34 am | News | Comments

Eli Lilly has reported fourth-quarter net income of $428.5M. On a per-share basis, the Indianapolis-based company said it had profit of 40 cents. Earnings, adjusted for asset impairment costs and costs related to mergers and acquisitions, came to 75 cents per share.

TOPICS:

Mylan Shareholders Approve Abbott Business Purchase

January 29, 2015 1:13 pm | News | Comments

Mylan announced that its shareholders approved its purchase of an Abbott Laboratories business and its tax-reducing move to the Netherlands. The company also said European Union regulators cleared the deal, which Mylan values at about $5.3 billion.

TOPICS:

AstraZeneca, MD Anderson Enter Collaboration to Help Improve Patient Outcomes in Ovarian/ Gynecologic Cancers

January 29, 2015 1:06 pm | News | Comments

AstraZeneca and The University of Texas MD Anderson Cancer Center today announced a multi-year, strategic research collaboration to conduct multiple, parallel clinical and clinically-related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes.

TOPICS:

FDA Approves IMBRUVICA for Treatment of Waldenstrom's Macroglobulinemia

January 29, 2015 12:54 pm | News | Comments

Pharmacyclics has announced that the FDA has granted single-agent IMBRUVICA (ibrutinib) regular (full) approval in all lines of therapy as the first and only treatment for patients with Waldenstrom's macroglobulinemia (WM), a rare, indolent type of B-cell lymphoma.

TOPICS:

Industry Group: Medical Device Tax Led to Thousands of Job Cuts

January 29, 2015 11:39 am | by Andrew Szal, Editor, Pharmaceutical Processing | News | Comments

The Advanced Medical Technology Association said the tax -- which was enacted as part of the Affordable Care Act to generate revenue for the law -- resulted in 4,500 job reductions in 2014.           

TOPICS:
Advertisement

California Declares Electronic Cigarettes a Health Threat

January 29, 2015 11:22 am | by FENIT NIRAPPIL, Associated Press | News | Comments

California health officials have declared electronic cigarettes a health threat that should be strictly regulated like tobacco products, joining other states and health advocates across the U.S. in seeking tighter controls as "vaping" grows in popularity.

TOPICS:

Lab Cleanroom Furniture

January 29, 2015 10:54 am | Product Releases | Comments

Range of cleanroom furniture is built from Trespa Toplab Base – a brand of high pressure laminate plate.  As well as being chemical-resistant and antistatic, it has low dirt pick-up, is easy to clean and is scratch-resistant, making it ideal for use in a controlled lab environment.

Vetter Completes Structural Work on New Multi-Functional Development Service and Information Technology Building

January 29, 2015 10:40 am | News | Comments

Following 16 months of construction, the first phase of a modern, multi-functional building at Vetter’s Ravensburg Schuetzenstrasse site has been completed. Estimated to be fully operational by the beginning of 2016, the new facility will contain high-tech laboratories and workplaces for Vetter Development Service, as well as a highly secure data center and additional office space for a total area of 8,500 sqm.

TOPICS:

Muscular Moves Toward Custom Medicine

January 29, 2015 10:32 am | Videos | Comments

Scientists at Duke University say they’ve created the first lab-grown human skeletal muscles that contract in response to electrical and other stimuli.                 

TOPICS:

New Link Between Household Chemicals and Early Menopause

January 29, 2015 10:22 am | Videos | Comments

Researchers say that common household chemicals found in cosmetics and plastics could accelerate menopause in women by up to four years.                    

TOPICS:

Study: Sponsors and CROs Implementing New Ways to Better Leverage Investigative Site Relationships

January 29, 2015 9:33 am | News | Comments

Improved investigative site relationship use and effectiveness are top objectives in 2015 for pharmaceutical companies and contract research organizations, according to drug industry R&D executives participating in a roundtable recently hosted by the Tufts Center for the Study of Drug Development.

TOPICS:

Epizyme Appoints President of Research

January 29, 2015 9:29 am | News | Comments

Epizyme has announced that Robert A. Copeland, Ph.D., has been named President of Research. Dr. Copeland, who was previously Executive Vice President of Research and Chief Scientific Officer at Epizyme, will continue to serve as Chief Scientific Officer.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading